Key result
ICDs anchor SCD prevention in HF, with AADs and ablation minimizing shocks.
Why the study?
Heart failure is increasingly prevalent and linked to ventricular arrhythmias, prompting a review of the underlying pathophysiology, disease burden, and available management strategies.
This review provides a comprehensive overview of the mechanisms and management of ventricular arrhythmias in heart failure, emphasizing the integration of medical therapy, ICDs, and catheter ablation.
Reinforces ICDs as SCD prevention mainstay in HF with adjuncts to curb shocks; leaves open optimal integration amid evolving therapies.
Heart failure is an increasingly prevalent condition, which is associated with ventricular arrhythmias. The reduction in cardiac pumping efficiency leads to the activation of several compensatory mechanisms. These mechanisms eventually lead to cardiac remodelling and a decline in haemodynamic status, contributing to the formation of a substrate conducive to arrhythmias, including increased automaticity, triggered activity, and, most commonly, re-entry circuits. In turn, ventricular arrhythmias can lead to the worsening of heart failure. A diagnosis of heart failure and ventricular arrhythmias is obtained using the patient’s history, examination findings, and investigation results. A key tool in this is echocardiogram imaging, which visualises the cardiac chambers, determines ventricular ejection fraction, and identifies structural abnormalities. A reduction in ejection fraction is a significant risk factor for the development of ventricular arrhythmias. Arrhythmias are diagnosed by ECG, Holter monitoring, and telemetry or event monitoring, and should initially be treated by optimising the medical management of heart failure. Anti-arrhythmic drugs, including beta-blockers, are usually the first-line therapy. Sudden cardiac death is a significant cause of mortality in heart failure patients, and implantable cardioverter defibrillator devices are used in both primary and secondary prevention. Anti-arrhythmic drugs and catheter ablation are important adjunctives for minimising shock therapy. In addition, autonomic modulation may offer a novel method of controlling ventricular arrhythmias. The objective of this review is to provide a practical overview of this rapidly developing field in relation to current evidence regarding the underlying pathophysiology, burden of disease, and management strategies available.
No takes yet. Share an insight, caveat, or question.
Noel Boyle (2019) conducted a review in Congestive Heart Failure and Ventricular Arrhythmias. Implantable cardioverter defibrillators, anti-arrhythmic drugs, and catheter ablation was evaluated. Implantable cardioverter defibrillators are the principal intervention for preventing sudden cardiac death in heart failure patients, with anti-arrhythmic drugs and catheter ablation serving as adjuncts to minimize shocks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: